Lead Product(s) : Emapticap pegol
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TME Pharma Announces Plan to Externalize and Monetize NOX-E36
Details : NOX-E36 (emapticap pegol) is an injectable PEGylated L-stereoisomer RNA aptamer that inhibits chemokine CCL2 and is in preclinical studies for early glaucoma treatment.
Product Name : NOX-E36
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Emapticap pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : vgAAV.GL
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases.
Product Name : vgAAV.GL
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : vgAAV.GL
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EYS809
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Korea Investment Partners
Deal Size : $12.0 million
Deal Type : Series B Financing
Eyevensys Raises $12M in a Series B Plus Funding Round
Details : The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye.
Product Name : EYS809
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 08, 2021
Lead Product(s) : EYS809
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Korea Investment Partners
Deal Size : $12.0 million
Deal Type : Series B Financing